Literature DB >> 12538861

Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Alan Charest1, Vicky Kheifets, Julie Park, Keara Lane, Kevin McMahon, Cathy L Nutt, David Housman.   

Abstract

Activating oncogenic mutations of receptor tyrosine kinases (RTKs) have been reported in several types of cancers. In many cases, genomic rearrangements lead to the fusion of unrelated genes to the DNA coding for the kinase domain of RTKs. All RTK-derived fusion proteins reported so far display oligomerization sequences within the 5' fusion partners that are responsible for oncogenic activation. Here, we report a mechanism by which an altered RTK gains oncogenic potential in a glioblastoma cell line. A microdeletion on 6q21 results in the fusion of FIG, a gene coding for a Golgi apparatus-associated protein, to the kinase domain of the protooncogene c-ROS. The fused protein product FIG-ROS is a potent oncogene, and its transforming potential resides in its ability to interact with and become localized to the Golgi apparatus. Thus we have found a RTK fusion protein whose subcellular location leads to constitutive kinase activation and results in oncogenic transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538861      PMCID: PMC298701          DOI: 10.1073/pnas.242741799

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).

Authors:  Géraldine Guasch; Cornel Popovici; Francine Mugneret; Max Chaffanet; Pierre Pontarotti; Daniel Birnbaum; Marie-Josèphe Pébusque
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

2.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

3.  Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates.

Authors:  W J Boyle; P van der Geer; T Hunter
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

4.  SH2 domains recognize specific phosphopeptide sequences.

Authors:  Z Songyang; S E Shoelson; M Chaudhuri; G Gish; T Pawson; W G Haser; F King; T Roberts; S Ratnofsky; R J Lechleider
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

5.  Characterization of the ros1-gene products expressed in human glioblastoma cell lines.

Authors:  S Sharma; C Birchmeier; J Nikawa; K O'Neill; L Rodgers; M Wigler
Journal:  Oncogene Res       Date:  1989

6.  Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule.

Authors:  H Matsushime; L H Wang; M Shibuya
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

7.  Differential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines.

Authors:  J K Wu; D M Chikaraishi
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

8.  Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.

Authors:  G A Rodrigues; M Park
Journal:  Mol Cell Biol       Date:  1993-11       Impact factor: 4.272

9.  Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.

Authors:  R Bookstein; J Y Shew; P L Chen; P Scully; W H Lee
Journal:  Science       Date:  1990-02-09       Impact factor: 47.728

10.  Transient and locally restricted expression of the ros1 protooncogene during mouse development.

Authors:  E Sonnenberg; A Gödecke; B Walter; F Bladt; C Birchmeier
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  32 in total

Review 1.  Detecting and targetting oncogenic fusion proteins in the genomic era.

Authors:  Monika A Davare; Cristina E Tognon
Journal:  Biol Cell       Date:  2015-04-07       Impact factor: 4.458

2.  Crystallization and preliminary X-ray crystallographic studies of the coiled-coil domain of PIST.

Authors:  Young Cheul Shin; Eun Kyoung Seo; Ju Hong Jeon; Hyun Ho Park
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-03-29

3.  Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Authors:  Zhifu Xiang; Frederike Kreisel; Jennifer Cain; AnnaLynn Colson; Michael H Tomasson
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

4.  Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases.

Authors:  Dirk-E Schmidt-Arras; Annette Böhmer; Boyka Markova; Chunaram Choudhary; Hubert Serve; Frank-D Böhmer
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

Review 5.  Recent Advances in Targeting ROS1 in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2017-08-14       Impact factor: 15.609

6.  Cytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma.

Authors:  Yong Cheng; Yang Sun; Li-Zhen Wang; You-Cheng Yu; Xiaojun Ding
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

7.  PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Authors:  Helen Y Zou; Qiuhua Li; Lars D Engstrom; Melissa West; Vicky Appleman; Katy A Wong; Michele McTigue; Ya-Li Deng; Wei Liu; Alexei Brooun; Sergei Timofeevski; Scott R P McDonnell; Ping Jiang; Matthew D Falk; Patrick B Lappin; Timothy Affolter; Tim Nichols; Wenyue Hu; Justine Lam; Ted W Johnson; Tod Smeal; Al Charest; Valeria R Fantin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

Review 8.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

9.  Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Authors:  Kurtis D Davies; Anh T Le; Mariana F Theodoro; Margaret C Skokan; Dara L Aisner; Eamon M Berge; Luigi M Terracciano; Federico Cappuzzo; Matteo Incarbone; Massimo Roncalli; Marco Alloisio; Armando Santoro; D Ross Camidge; Marileila Varella-Garcia; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2012-08-23       Impact factor: 12.531

Review 10.  Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Authors:  Justin F Gainor; Alice T Shaw
Journal:  Oncologist       Date:  2013-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.